A5039236729- Liver Diseases and Immunity
- Liver Disease Diagnosis and Treatment
- Inflammatory Bowel Disease
- Hepatitis B Virus Studies
- Celiac Disease Research and Management
- Liver Disease and Transplantation
- Gallbladder and Bile Duct Disorders
- Hepatitis C virus research
- Hepatitis Viruses Studies and Epidemiology
- Pediatric Hepatobiliary Diseases and Treatments
- Microscopic Colitis
- Liver physiology and pathology
- Systemic Lupus Erythematosus Research
University Medical Center Hamburg-Eppendorf
2022-2025
Universität Hamburg
2022-2025
ERN RARE-LIVER
2023
Primary sclerosing cholangitis (PSC) is frequently associated with inflammatory bowel disease (IBD).1 The type of IBD (ulcerative colitis or Crohn's disease) was shown to associate PSC outcome, but a clear understanding the pathogenetic link between activity and lacking.2-4 Tofacitinib, mainly inhibiting Janus-Kinase (JAK) 1/3 pathway, has been approved for treatment ulcerative colitis.5 aim this study assess safety efficacy tofacitinib in patients PSC-IBD, including liver outcomes.
The European Reference Network on Hepatological Diseases (ERN RARE-LIVER) launched the prospective, multicentre, quality-controlled R-LIVER registry rare liver diseases. aim of this study was to assess presentation and outcome autoimmune hepatitis (AIH) after 1 year treatment.
Abstract Background The majority of patients with primary sclerosing cholangitis (PSC) have inflammatory bowel disease (IBD). This association has fostered several pathogenic hypotheses linking mucosal immunity to hepatobiliary inflammation. A putative therapeutic target along this axis centres on gut-derived IL-17 secretor cell subtypes, which are activated by interleukin (IL)23. Notably, emergent forms IBD treatment host anti-IL23 agents, however safety and efficacy data in PSC is limited....
There is little data on the hepatic efficacy and safety of immunomodulatory drugs used in patients with autoimmune hepatitis (AIH), despite their established use dermatology, rheumatology inflammatory bowel diseases (IBD). Our aim was to collect real-life experience expert centres treating AIH these drugs, considered unconventional for management.
Zu den autoimmunen Lebererkrankungen gehören die autoimmune Hepatitis (AIH), primär biliäre Cholangitis (PBC) und sklerosierende (PSC). Diagnostik, Therapie Surveillance dieser Erkrankungen sind aufwendig. Dieser Beitrag widmet sich der Versorgung mit dem Fokus auf neue klinische Aspekte über kondensierte Darstellung aktuellen leitliniengerechten hinaus.
Background/Aims We collected data on Primary Sclerosing Cholangitis (PSC) patients with associated inflammatory bowel disease (IBD) who received past or ongoing treatment tofacitinib to assess safety and efficacy of liver disease.
Im 1. Teil der Reihe „Autoimmune Lebererkrankungen – ein Update (Teil 1)“ wurden die Grundlagen zur Diagnostik und Surveillance autoimmuner autoimmune Hepatitis (AIH) behandelt In diesem 2. werden mit primär biliären Cholangitis (PBC) sklerosierenden (PSC) cholestatische beleuchtet.
Background and Aims Prospective multicentre data on adult patients with autoimmune hepatitis (AIH) in Western countries is lacking. To address this, the European Reference Network for Hepatological Diseases (ERN RARE-LIVER) launched prospective, quality-controlled R-LIVER registry newly diagnosed people AIH. Our aim was to assess therapeutic strategies outcome AIH across different countries.